GET DAILY SIGNALSISRG vs PRCT: Weighing an Established Robotic Surgery Leader Against an Emerging Urology Challenger
Key Takeaways
- ISRG (Intuitive Surgical) stands as a large-cap, profitable leader in robotic-assisted surgery, whereas PRCT (PROCEPT BioRobotics) represents a smaller, high-growth but still unprofitable company focused on urology.
- Both firms posted solid revenue increases in recent quarters, yet ISRG benefits from greater scale and a recurring-revenue model, while PRCT continues to navigate early-stage profitability and cash usage.
- Performance over the past year has diverged, with ISRG recovering from summer lows and PRCT trading well below its 52-week high amid softer legacy-system utilization.
- Tickeron AI Verdict: The AI currently leans toward ISRG due to its steadier trend, stronger stability, and broader recurring-revenue foundation compared with PRCT.
- For additional context, review ISRG Major News and ISRG Today's Price Move, along with PRCT Major News and PRCT Today's Price Move.
Setting the Stage for the Comparison
Investors following medical technology frequently compare established leaders with fast-growing disruptors. This stock comparison looks at ISRG (Intuitive Surgical) and PRCT (PROCEPT BioRobotics), two companies active in surgical robotics but at very different points in their development. ISRG operates as a global leader with a dominant installed base and consistent profits, while PRCT is an emerging specialist in urology that is still working toward profitability. The differences in market positioning, growth drivers, and risk profiles make this comparison useful for investors choosing between a more stable franchise and a higher-risk, higher-growth opportunity in the same broad sector.
Insights into ISRG's Recent Results
ISRG, Intuitive Surgical, develops and markets the da Vinci and Ion robotic-assisted surgery platforms used in general, thoracic, and urologic procedures. The business relies on a recurring-revenue model where instruments, accessories, and services tied to an installed base of more than 12,000 da Vinci systems account for a substantial portion of revenue. In recent weeks the company reported strong top-line results, with quarterly revenue rising about 22% year over year and worldwide procedures up roughly 15%, including a 31% increase in Ion procedures. Sentiment has been tempered, however, by slower U.S. da Vinci procedure growth and a $450 million antitrust litigation charge that reduced reported earnings, even though adjusted EPS beat estimates. The stock remains well below its 52-week high, reflecting ongoing valuation and competitive concerns despite resilient demand. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
PRCT's Performance and Challenges
PRCT, PROCEPT BioRobotics, develops the AquaBeam and HYDROS robotic systems for Aquablation therapy, a waterjet-based treatment for benign prostatic hyperplasia. The company has built a global installed base of roughly 1,100 systems and continues to expand adoption. Recent results have been mixed: quarterly revenue grew about 18% year over year but came in slightly below consensus, while net losses widened as operating expenses rose to support commercialization and direct-to-patient marketing. Investors are watching utilization at legacy AquaBeam accounts, where growth has softened even as newer HYDROS accounts show stronger usage. Ongoing securities litigation and an unprofitable bottom line have added to volatility, and the stock trades well below its prior-year highs.
Key Differences at a Glance
The two companies share a robotics theme but differ sharply in scale and economics. ISRG is a diversified, profitable enterprise with roughly $156 billion in market capitalization, a broad procedure mix, and durable recurring revenue from its large installed base. Its main trade-offs are valuation and decelerating U.S. procedure growth. PRCT is a roughly $1 billion market-cap company concentrated in urology, with faster revenue growth but persistent net losses and cash burn. Its growth depends on the HYDROS upgrade cycle and procedure adoption, while risks include legal exposure, competition from larger device makers, and uncertainty around legacy-system utilization. On risk factors, ISRG offers greater financial stability but more modest growth; PRCT offers higher growth potential with substantially greater execution and volatility risk.
AI Assessment and Outlook
Based on factors such as trend consistency, stability, catalysts, and relative positioning, Tickeron’s AI would likely favor ISRG over PRCT in the current environment. ISRG shows a more established trend, a profitable recurring-revenue model, and a large installed base that supports resilience even as near-term headwinds persist. PRCT carries a compelling growth narrative but presents a more volatile profile with an unprofitable bottom line and softer utilization signals. The AI’s assessment is probabilistic rather than definitive, reflecting the relative stability and broader market positioning that ISRG currently offers compared with PRCT.
Exploring Automated Trading Strategies
When evaluating how different automated approaches are positioned in the current market, I often review Tickeron’s Trending AI Robots. The page highlights a curated selection of AI-powered trading bots chosen for their suitability to prevailing conditions. These bots span a range of styles, strategies, and risk parameters, allowing users to explore automated systems that align with specific objectives rather than relying on a single approach.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Aroon Indicator for ISRG shows an upward move is likely
ISRG's Aroon Indicator triggered a bullish signal on November 09, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 265 similar instances where the Aroon Indicator showed a similar pattern. In 188 of the 265 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +10.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where ISRG advanced for three days, in 211 of 313 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
Bearish Trend Analysis
The 10-day RSI Indicator for ISRG moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 13 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 34%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 62 cases where ISRG's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 65%.
The Moving Average Convergence Divergence Histogram (MACD) for ISRG turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 31 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ISRG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
ISRG broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. ISRG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 51 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 69 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ISRG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.805) is normal, around the industry mean (4.964). P/E Ratio (51.222) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (1.931) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (12.469) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of robotic technologies used for surgeries
Industry PharmaceuticalsOther
Advertisement